Nedumaan Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 6 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth 1049.51%
- Profit Growth -456.70%
- Ebitda -456.33%
- Net Worth -30.75%
- Total Assets 33.54%
About Nedumaan Pharmaceutical
Nedumaan Pharmaceutical Private Limited (NPPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 24 July 2019 (Five years and six months 25 days old ). Its registered office is in Kanpur Nagar, Uttar Pradesh, India.
The Corporate was formerly known as Nedumaan Fashion Private Limited. The Company is engaged in the Home & Lifestyle Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Akhilesh Kumar and Dhirendra Srivastav serve as directors at the Company.
Company Details
-
Location
Kanpur Nagar, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U17299UP2019PTC119407
-
Company No.
119407
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
24 Jul 2019
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Nedumaan Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akhilesh Kumar
|
Director | 24-Jul-2019 | Current |
|
Dhirendra Srivastav
|
Director | 24-Jul-2019 | Current |
Financial Performance of Nedumaan Pharmaceutical.
Nedumaan Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 1049.51% increase. The company also saw a substantial fall in profitability, with a 456.7% decrease in profit. The company's net worth observed a substantial decline by a decrease of 30.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nedumaan Pharmaceutical?
In 2021, Nedumaan Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Blackeel Industries Private LimitedAkhilesh Kumar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nedumaan Pharmaceutical?
Unlock and access historical data on people associated with Nedumaan Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nedumaan Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nedumaan Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.